Alemtuzumab gets two bites of the cherry. #MSBlog #MSResearch
"The following press release from Genzyme indicates that the FDA will reassess alemtuzumab via a standard route rather than via an appeal process. Maybe MSers in the US will get access to this drug before the end of the year."
Labels: Alemtuzumab, FDA